<DOC>
	<DOC>NCT02231372</DOC>
	<brief_summary>Tolerability, efficacy and handling of Berodual® Respimat® 20/50µg/dose solution for inhalation in patients with chronic obstructive airways disease in daily practice</brief_summary>
	<brief_title>Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Fenoterol, ipratropium drug combination</mesh_term>
	<mesh_term>Fenoterol</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Men and women presenting with symptoms of chronic obstructive pulmonary disease Both previously untreated patients and patients treated previously with Berodual® or with other antiobstructive respiratory tract agents may be included Patients presenting with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>